Digestive

Press enter to search
Close search
Open Menu

Digestive

News and information on digestive health products, merchandising and trends in retail pharmacies.

FDA calls for removal of ranitidine products from market

The Food and Drug Administration has requested that manufacturers withdraw all prescription and OTC ranitidine drugs from the market immediately.

Perrigo closes acquisition of Prevacid 24HR OTC rights

Perrigo has completed its acquisition of the OTC rights to Prevacid 24HR.

upspring Stomach Settle Drops

UpSpring is growing its selection beyond only health-and-wellness products for moms and babies into family wellness while also growing its selection available at Walmart.

Flatu-Scents’ Internal Deodorant is a vegan capsule that aims to make users feel more comfortable and stop any foul-smelling gas, company said.

Good Culture’s Wellness Probiotic Gut Shots contain such ingredients as turmeric, matcha, chaga and collagen, the company said.

The Prevacid 24HR brand and generic had a market value of approximately $57 million for the most recent 12 months ended August 2019, according to IQVIA.

Procter & Gamble is broadening the offerings available from its Pepto Bismol brand.

Though March saw the return to daylight saving time and the NCAA Division I Men’s Basketball Tournament, the new product team at Hamacher Resource Group still found time to assess 445 new products and select five standouts.

New data from the Consumer Healthcare Products Association and IRI is highlighting the ripple effect that a consumer buying an OTC product can have on the American healthcare system — namely, some $146 billion in savings.

The company has introduced its Probiotic + Colostrum (Powder for Kids) and Babies, as well as Stomach Settle Nausea Relief Drops, to Target’s digestive health assortment.

As 2018 came to a close, the new product team at Hamacher Resource Group was unrelenting in its efforts to find the hottest products introduced in December.

GlaxoSmithKline will have a controlling 68% equity interest and Pfizer will have a 32% equity interest in the joint venture, which would have a global OTC market share of 7.3%, leading the market in most key geographical areas, including the United States and China.

FDA's decision impacts five manufacturers with PEG 3350 ANDA approvals, including Kremers Urban Pharmaceuticals, Breckenridge Pharmaceutical, Nexgen Pharma, Paddock Laboratories and Teva Pharmaceutical.

Alphonso’s TS Kelly takes a look at how OTC heartburn makers grab share of mind and dollars through strategic ad buys.

Show More